52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
* HELIUS MEDICAL TECHNOLOGIES - IF CO FAILS TO ENSURE COMMERCIALIZATION OF PONS TREATMENT IS AVAILABLE FOR U.S. GOVERNMENT BY DEC. 31, 2021, CO MAY FORFEIT RIGHT TO PURSUE COMMERCIALIZATION
* HELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES UPLISTING TO NASDAQ AND PRICING OF PUBLIC OFFERING OF CLASS A COMMON STOCK AND WARRANTS
* Helius Medical Technologies announces launch of sixth site for pivotal mild to moderate traumatic brain injury clinical trial Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.